Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
/
Shield Therapeutics
STX
Shield Therapeutics
Global Aging Trends And Early Detection Will Unlock Markets
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
03 Aug 25
Updated
08 Aug 25
5
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
UK£0.14
66.5% undervalued
intrinsic discount
08 Aug
UK£0.046
Loading
1Y
19.5%
7D
2.2%
Author's Valuation
UK£0.1
66.5% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
UK£0.1
66.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-49m
221m
2014
2017
2020
2023
2025
2026
2028
Revenue US$221.4m
Earnings US$57.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
28.98%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
US$57.64m
Earnings '28
x
8.93x
PE Ratio '28
=
US$515.01m
Market Cap '28
US$515.01m
Market Cap '28
/
2.29b
No. shares '28
=
US$0.23
Share Price '28
US$0.23
Share Price '28
Discounted to 2025 @ 6.82% p.a.
=
US$0.18
Fair Value '25
US$0.18
Fair Value '25
Converted to GBP @ 0.7439 USD/GBP Exchange Rate
=
UK£0.13
Fair Value '25